Evidence map›Paper›PMID 22136142›Full record

ArticleImmunology2012

Depletion of complement does not impact initiation of xenobiotic-induced autoimmune disease.

David M Cauvi, Christopher B Toomey, K Michael Pollard

Open access · greenAbstract read
In one paragraph

Article in Immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Mercury-induced inflammation and autoimmunity.Biochimica et biophysica acta. General subjects · 2019
    Review
  2. Complement and CD4eLife · 2019
    Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

David M CauviDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.
Christopher B Toomey
K Michael Pollard
Scripps Research Institute · US

Funding

MERCURY INDUCED AUTOIMMUNITYR01ES007511 · NIEHS · SCRIPPS RESEARCH INSTITUTE, THE · PI POLLARD, KENNETH MICHAEL · 1997 to 2007
$2.1M
Role of Daf in Systemic AutoimmunityR01ES014847 · NIEHS · SCRIPPS RESEARCH INSTITUTE, THE · PI POLLARD, KENNETH MICHAEL · 2008 to 2012
$1.9M
NIEHS NIH HHS ES007511NIEHS NIH HHS ES014847NIEHS NIH HHS R01 ES007511NIEHS NIH HHS R01 ES014847
6 · The paper itself

Abstract

Deficiency in Daf1, a complement regulatory protein, has been shown to exacerbate development of various autoimmune diseases and recent studies have suggested that this may be explained by Daf1 acting to limit T-cell hyper-responsiveness. It has been suggested that the absence of Daf1 aggravates autoimmune disease in a complement-dependent manner, but others have shown that activation of T cells in the absence of Daf1 can be complement independent. However, the relationship between Daf1, complement components, lymphocyte activation, cytokine expression and antibody production remains to be determined in mice that are not Daf1 deficient. We have recently demonstrated, in murine mercury-induced autoimmunity (mHgIA), that an accumulation of CD44(high) Daf(low) CD4(+) T cells is associated with the development of autoimmunity. In this study we observed that complement depletion does not affect the accumulation of activated CD4(+) T cells, elevation of splenic interleukin-4 expression and autoantibody production in mHgIA. In addition, neither the accumulation of CD44(high) Daf(low) CD4(+) T cells nor the down-regulation of Daf1 expression on CD4(+) T cells was influenced by a lack of complement. In conclusion, these studies show that initiating events in xenobiotic-induced autoimmunity, including lymphocyte activation, cytokine expression and autoantibody production, are not dependent on complement.

Indexed as

AnimalsAutoantibodiesAutoimmune DiseasesAutoimmunityCD4-Positive T-LymphocytesCD55 AntigensComplement C3Complement Inactivating AgentsComplement System ProteinsCytokinesElapid VenomsLymphocyte ActivationMercuric ChlorideMiceMice, KnockoutXenobioticsAutoantibodiesCD55 Antigenscobra venom factorComplement C3Complement Inactivating AgentsComplement System ProteinsCytokinesdecay-accelerating factor 1, mouseElapid VenomsMercuric ChlorideXenobiotics

Identifiers

PMID22136142
PMCPMC3372748
OpenAlexW1540726419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.